Neumora Therapeutics
NMRA
38 hedge funds and large institutions have $512M invested in Neumora Therapeutics in 2023 Q3 according to their latest regulatory filings, with 38 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
23.84% more ownership
Funds ownership: 0% → 23.84% (+24%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SoftBank Group
Tokyo,
Japan
|
+$95.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$70.3M |
| 3 |
MCMU
MIC Capital Management (UK)
London,
United Kingdom
|
+$55.7M |
| 4 |
WT
Wellcome Trust
London,
United Kingdom
|
+$41.4M |
| 5 |
AG
Artal Group
Luxembourg
|
+$35M |
Top Sellers
NMRA Hedge Fund Activity: Q3 2023 in Review
38 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Neumora Therapeutics (NMRA) for Q3 2023, worth a combined $512M.
Buyers outnumbered sellers: 38 funds opened new NMRA positions and 0 closed out — a net gain of 38 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was SoftBank Group, opening a new position worth an estimated $95.6M.
- 38 institutional investors held Neumora Therapeutics (NMRA) as of Q3 2023, up from 0 in Q2 2023.
- Funds reported $512M of Neumora Therapeutics stock for Q3 2023.
- 38 funds opened new Neumora Therapeutics positions in Q3 2023 and 0 closed out, a net change of +38 holders.
- The largest Neumora Therapeutics buyer in Q3 2023 was SoftBank Group, an estimated $95.6M added.
Based on aggregated 13F filings for Q3 2023.